Compare Comcast Corporation (CMCSA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Sanofi SA — how do they compare? Comcast Corporation trades at $25.3 (market cap $91.02B), while Sanofi SA trades at $43.44 (market cap $104.30B). The key difference: Comcast Corporation and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| CMCSA | SNY | |
|---|---|---|
Market Cap | $91.02B | $104.30B |
Sector | Media | Health |
52-Week High | $32.50 | $52.34 |
52-Week Low | $21.92 | $41.33 |
Enterprise Value | $173.74B | $124.19B |
Dividend Yield | 5.15% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.20, down 0.63% today, with strong fundamentals including a P/E of 8.22 and net income margin of 8.97%. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI indicates potential overbought conditions. Recent earnings beats and a planned NBCUniversal spinoff provide positive catalysts, while analyst consensus remains strongly bullish with a $27.78 price target.
CMCSA presents compelling value with discounted valuation multiples and consistent cash flow generation. Key opportunities include wireless growth and media separation, while risks involve competitive pressures and potential economic headwinds affecting consumer spending. The stock offers a balanced risk-reward profile for long-term investors seeking stable returns.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
